SPC Financial Inc. Takes Position in Omeros Co. (NASDAQ:OMER)

SPC Financial Inc. purchased a new position in shares of Omeros Co. (NASDAQ:OMER) in the 3rd quarter, HoldingsChannel.com reports. The fund purchased 19,400 shares of the biopharmaceutical company’s stock, valued at approximately $77,000.

Other hedge funds have also recently modified their holdings of the company. Susquehanna Fundamental Investments LLC purchased a new position in shares of Omeros in the first quarter valued at approximately $538,000. Vanguard Group Inc. lifted its holdings in Omeros by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after purchasing an additional 81,348 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares during the last quarter. AQR Capital Management LLC purchased a new stake in shares of Omeros during the second quarter worth $105,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Omeros in the first quarter valued at about $85,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Performance

Shares of Omeros stock opened at $4.14 on Friday. The business’s 50 day moving average price is $3.98 and its 200 day moving average price is $3.92. The company has a market cap of $239.89 million, a price-to-earnings ratio of -2.10 and a beta of 1.48. Omeros Co. has a one year low of $1.05 and a one year high of $5.68.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter. On average, analysts predict that Omeros Co. will post -2.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Friday, August 16th.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.